Effects of Milk Powder Intervention on Body Composition and Physical Performance in Middle-aged and Older Adults
Launched by HUILIAN ZHU · May 20, 2024
Trial Information
Current as of August 19, 2025
Not yet recruiting
Keywords
ClinConnect Summary
This clinical trial is looking at how a special formula milk powder affects body composition and physical performance in middle-aged and older adults over a period of 24 weeks. The goal is to see if this milk powder can help improve health compared to regular milk powder and a group that doesn’t receive any milk powder intervention. The study is not yet recruiting participants, but when it begins, it will involve adults aged 50 and older who have a body mass index (BMI) of less than 22 and meet specific health criteria.
To be eligible, participants must live in Guangzhou and not plan to move in the next six months. They should also be able to commit to the study and not have any severe health issues or lactose intolerance. Participants can expect to take part in the study for about six months, during which they will receive either the formula milk powder or regular milk powder while their body composition and physical performance are monitored. This research aims to help us understand how nutrition can support healthy aging.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Aged 50 years old and older;
- • BMI \<22kg/m2;
- • Calf circumference \<33cm in women or \<34cm in men, or SARC-F ≥ 4, or SARC-Claf ≥ 11;
- • Living in Guangzhou and having no plan to move in the next 6 months;
- • Willing to participate in the study.
- Exclusion Criteria:
- • Lactose intolerance;
- • Complicated with severe diseases;
- • Unable to conduct study procedures;
- • Participating in any other intervention studies.
About Huilian Zhu
Huilian Zhu is a dedicated clinical trial sponsor committed to advancing medical research and innovation. With a focus on high-quality, patient-centered studies, Huilian Zhu collaborates with various stakeholders, including healthcare professionals, regulatory bodies, and research institutions, to ensure the successful design and execution of clinical trials. Their expertise spans multiple therapeutic areas, emphasizing ethical practices, rigorous methodologies, and compliance with regulatory requirements. By fostering a culture of collaboration and transparency, Huilian Zhu aims to contribute significantly to the development of effective therapies that improve patient outcomes and enhance public health.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported